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INTRODUCTION
Ecdysteroids are widely marketed to athletes as dietary supplement, 
advertising to increase strength and muscle mass during resistance 
training, to reduce fatigue and to ease recovery. Several studies have 
reported a wide range of pharmacological effects of ecdysteroids in 
mammals, most of them beneficial to the organism. In the 1980s 
the most active phytoecdysteroid, ecdysterone (beta-ecdysone, a 
“Russian secret”), was suspected to be used by Russian Olympic 
athletes. The levels of ecdysteroids in western diet are generally low 
(usually in the range of less than 1 mg · day-1), while the doses used 
by bodybuilders are stated in a range of up to 1000 mg · day-1.
Extensive investigations on the possible growth-promoting ef-
fects of ecdysterone in various animal species (rats, mice, Japanese 
quail and cattle) and in humans [1-13] were reported and lots of 
rumors on its misuse by athletes are circulating since then. Ecdys-
terone has been demonstrated to increase protein synthesis in 
skeletal muscle [14]. Gorelick et al. proposed direct or indirect 
stimulation of the PI3K/Akt signaling pathway as mechanism for 
this increased protein synthesis [9, 15].
Conversely to anabolic-androgenic steroids (AAS) that increase 
muscle mass mainly through their binding to the androgen recep-
tor (AR), no nuclear receptor that is homologous to the ecdysone 
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nuclear receptor found in insects has yet been described in mam-
mals so far [9]. Only recently, binding of ecdysterone to the human 
ERβ (ED50 = 13 nM) could be shown in cell culture experiments 
and induction of hypertrophy in C2C12 cells was shown to be 
mediated by the ERβ activation [2]. The aim of this study was to 
elucidate the anabolic potency of ecdysterone in comparison to 
other known anabolic agents and to support the hypothesis of ERβ 
mediated action by in-silico modelling.
MATERIALS AND METHODS 
In-Vitro Hypertrophy Model. The anabolic properties of ecdyster-
one were tested by incubation of C2C12 derived myotubes with the 
test compounds and determination of diameters of 47 myotubes per 
group (mean of measurements every 10–20 µm along the myotube) 
as described before [2]. Concentrations applied in this study were 
1 µM for ecdysterone and dihydrotestosterone (chemical structures 
in Figure 1) and 1.3 nM for the growth factor IGF-1.
Animal Study
Male Wistar rats (n=42, Janvier, Le-Genest St-Isle, France) were 
randomly allocated to verum and control groups. The animals were 
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kept under controlled conditions (T=20 ± 1°C, relative humidity 
Φ=50–80%, 12-h light/12-h dark) with free access to standard diet 
(SSniff GmbH, Soest, Germany) and water. To mimic the situation in 
athletes, intact (i.e. non-castrated) animals were treated with 5 mg · kg-1 
body weight of the respective substance once daily for 21 days. Verum 
groups received injections of ecdysterone, metandienone, estradien-
edione, or S-1, each diluted in a solution of 20% DMSO and 80% 
peanut oil. The control groups were injected with vehicle only. The 
animals were handled in compliance with accepted veterinary medi-
cal practice and with the approval of the Animal Welfare Committee. 
Further experimental details were performed as described earlier [2]. 
The anabolic potency of ecdysterone was determined using the 
muscle fiber size of the soleus muscle of male Wistar rats as measure. 
The effect was compared to the anabolic androgenic steroids metan-
dienone (dianabol) and estradienedione (trenbolox) as well as the 
selective androgen receptor modulator S-1 (chemical structures in 
Figure 1). 
In-silico Modeling of Steroid Receptor Binding
Molecular modeling experiments were conducted to support the data 
that the anabolic effect of ecdysterone is mediated by ERβ binding, 
rather than AR, as known for classical anabolic androgenic steroids. 
Thus, ecdysterone was docked into crystal structures of the two 
subtypes ERα and ERβ as well as the AR (PDB entries 3UUD [16] 
for ERα, 3OLL [17] for ERβ, and 2AM9 for AR [18], respectively). 
These crystal structures represent complexes with estradiol for the 
ER and testosterone for the AR to make sure they represent the 
protein conformation relevant for agonism. The docking experiment 
was performed using the software GOLD [19] allowing side chain 
flexibility in the binding regions to allow adaptions to the signifi-
cantly larger ligand ecdysterone. Binding poses were analyzed for 
key interaction features using the 3D pharmacophore modeling plat-
form LigandScout [20, 21]. 
Statistics
Statistical data evaluation was performed by Kruskal–Wallis test 
followed by pair-wise comparison with the Mann–Whitney U-test. 
Box and whisker plots in Figure 2 and Figure 3 represent minimum, 
25th, 50th (median), 75th percentile, and maximum of the distribu-
tion. Significance level was established at p ≤ 0.05.
FIG. 2. Effects of DHT (10-6 M), IGF-1 (10 ng · mL-1), and ecdysterone 
(Ecdy, 10-6 M) on the diameter of C2C12 myotubes. Determination 
of diameters of 47 myotubes per group. 
No significant differences within treatment groups, *significant 
versus control, p ≤ 0.05 by Kruskal–Wallis H-test and Mann–
Whitney U-test
FIG. 3. Anabolic effect of ecdysterone (Ecdy) expressed as fiber size 
of soleus muscle in intact rats. 
Significantly higher increase of fiber size of soleus muscle after 
Ecdy compared to estradienedione (EDD), metandienone (MD) and 
SARM S 1 (S1), *significant versus control, + significant versus 
Ecdy, p ≤ 0.05 by Kruskal–Wallis H-test and Mann–Whitney U-test
FIG. 1. Chemical structure of ecdysterone (A) as well as of the other anabolic agents used for comparison (B: selective androgen receptor 
modulator (SARM) S-1, C: anabolic androgenic steroid (AAS) metandienone, D: AAS dihydrotestosterone, E: AAS estradienedione)
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RESULTS 
Determination of Anabolic Properties. C2C12 derived myotubes 
were used as in-vitro model for testing anabolic activities. Incuba-
tion with ecdysterone showed significantly increased myotube di-
ameters compared to vehicle treated control cells (Figure 2). Com-
paring the effect with the endogenous anabolic androgenic steroid 
dihydrotestosterone at the same concentration and the anabolic 
growth factor IGF-1 (concentration for comparison was 1.3 nM) a 
slightly higher (not statistically significant) effect was observed. 
To mimic the situation in athletes, intact male Wistar rats were 
treated with the test components for 21 days. Significantly increased 
fiber sizes of the soleus muscle were determined following treatment 
with ecdysterone. Comparison with the animals treated with the 
anabolic androgenic steroids metandienone or estradienedione and 
the SARM S-1 yielded a significantly higher effect in the ecdyster-
one treated animals when the same doses were applied (Figure 3). 
In-silico Investigation of Steroid Receptor Binding
To underline the plausibility of the proposed ERβ mediated anabolic 
mechanism, ecdysterone molecular docking experiments into the 
human sex steroid receptors were conducted to derive mechanistic 
insights into ecdysterone binding.
Compared to the x-ray structure of the AR/testosterone complex, 
in-silico molecular docking of ecdysterone in the AR revealed an 
FIG. 4. ERα (PDB 3UUD [16], top) and ERβ (PDB 3OLL[17], bottom) with in-silico docked ecdysterone. 
ERβ forms additional hydrogen bonds with Met343 to a hydroxyl group of ecdysterone and with the protein backbone to the terminal 
alkyhydroxyl group. Arrows indicate hydrogen bonds (green: donor, red: acceptor), while yellow spheres show hydrophobic interactions. 
Residue numbering was chosen according to the used PDB entries.
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unfavorable binding pose and a completely different three dimen-
sional orientation in the AR/ecdysterone complex: At those positions 
where methyl groups are found for the endogenous ligand testoster-
one, hydroxyl groups sterically interfere with the receptor in case of 
ecdysterone. In addition, a water molecule mediating important in-
teraction in the testosterone complex is replaced by a methyl group 
for the ecdysterone docking pose resulting in an unfavorable interac-
tion pattern.
In contrast, both ER isoforms offer a binding side shape more 
suitable to accommodate ecdysterone. Docking poses in both subtypes 
share several interactions shown in Figure 4. Three additional hy-
drogen bonds are exclusively formed in the docking pose of ecdys-
terone in ERβ, which may explain the experimentally observed isoform 
preference [2, 22]: In ERβ the ligand can adapt a conformation close 
enough to Met343 and form a hydrogen bond with the hydroxyl group 
in position 2 of ecdysterone. Additionally, two more hydrogen bonds 
with the terminal hydroxyl group to the backbone of the β-subtype 
(Leu346, Phe404 and Leu387, respectively) could be observed.
DISCUSSION 
The data reported in here demonstrate that ecdysterone induces 
hypertrophy of muscles with a comparable or even higher potency 
as shown for anabolic androgenic steroids, SARMs or IGF-1. Analo-
gous findings were also reported by Syrov et al. [14]. They reported 
increased body weight gain and weight as well as increased protein 
content of the tibialis muscle in rats after ecdysterone administration 
(5 mg · kg-1 BW, orally, for 10 days). 
The generated docking poses support the hypothesis that ecdys-
terone shows no significant binding at the AR, but to ER with prefer-
ence to the ERβ subtype.
CONCLUSIONS 
An anabolic activity of ecdysterone was clearly confirmed by our 
investigation. The anabolic potency of the ecdysterone was compa-
rable or even higher as found for the anabolic androgenic steroids, 
SARMs or IGF-1. Moreover in-silico docking experiments support 
the postulated non-androgenic mechanism of ecdysterone. More 
likely and in agreement to the experimental data anabolic activity of 
ecdysterone is mediated via binding to the ER particularly ER beta. 
With respect to doping prevention the high anabolic potency of ecdys-
terone justifies its classification as an anabolic agent and therefore 
needs to be listed in the category “S1 Anabolic Agents” of the list of 
prohibited substances of the World Anti-Doping Agency
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